Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of LAIV4 in Children With Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03600428
Recruitment Status : Completed
First Posted : July 26, 2018
Last Update Posted : April 10, 2020
Sponsor:
Collaborators:
Centers for Disease Control and Prevention
Duke University
Children's Hospital Medical Center, Cincinnati
Information provided by (Responsible Party):
Buddy Creech, Vanderbilt University Medical Center

Brief Summary:
This is a prospective randomized, open label clinical trial in approximately 300 children aged 5-11 years with a physician diagnosis of persistent asthma. Participants will be randomized 1:1 to receive either a single intranasal dose of licensed quadrivalent LAIV (LAIV4) or an intramuscular injection of quadrivalent IIV4 (IIV4).

Condition or disease Intervention/treatment Phase
Asthma in Children Vaccine Adverse Reaction Vaccine Reaction Asthma Wheezing Influenza Biological: Live Attenuated Influenza Vaccine (LAIV) Biological: Inactivated Influenza Vaccine (IIV) Phase 4

Detailed Description:
The study will be conducted at three sites: Vanderbilt University Medical Center (Lead site), Cincinnati Children's Hospital Medical Center (contributing site), and Duke University Medical Center (contributing site) during the 2018-2019 influenza season. Participants will be randomized 1:1 to receive either a single intranasal dose of licensed quadrivalent LAIV (LAIV4) or an intramuscular injection of quadrivalent IIV4 (IIV4), stratifying by asthma severity (mild vs. moderate-to-severe). Vanderbilt will enroll about 100 participants, Cincinnati will enroll about 110 participants, and Duke will enroll about 90 participants. After enrollment, participants will be followed for 43 days via 5 additional phone, email, or text visits to monitor systemic reactogenicity, asthma symptoms and exacerbations, and serious adverse events. The primary objective is to compare proportions of participants with asthma exacerbations during the 42 days after LAIV4 versus IIV4. Because of the potential for increased risk of wheezing after LAIV, the use of LAIV in persons with asthma has been an area of vaccine safety research for many years; the safety issue remains unresolved. A clinical study to assess the safety of LAIV4 in children with asthma could expand the evidence base and inform clinical decision-making and public health policy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Clinical Study of the Safety of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) in Children With Asthma of Varying Levels of Severity
Actual Study Start Date : October 15, 2018
Actual Primary Completion Date : March 20, 2020
Actual Study Completion Date : March 20, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma Flu Flu Shot

Arm Intervention/treatment
Experimental: Live Attenuated Influenza Vaccine (LAIV)
Participants will receive one dose of live attenuated influenza vaccine via intranasal spray (administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril, each sprayer contains 0.2 mL of vaccine)).
Biological: Live Attenuated Influenza Vaccine (LAIV)
1 dose, 0.2 mL, intranasal administration

Active Comparator: Inactivated Influenza Vaccine (IIV)
Participants will receive one dose of inactivated influenza vaccine via intramuscular injection (0.5 mL).
Biological: Inactivated Influenza Vaccine (IIV)
1 dose, 0.5 mL, intramuscular administration




Primary Outcome Measures :
  1. Comparison of the proportion of participants experiencing an asthma exacerbation during the 42 days after LAIV4 vs. IIV4 (until day 43). [ Time Frame: Day 43 ]
    For this study, asthma exacerbation will be defined as: any acute episode of progressively worsening shortness of breath (dyspnea), cough, wheezing, chest tightness, and/or respiratory distress during the 42 days (until day 43) after influenza vaccination for which the patient seeks unscheduled medical attention (e.g., healthcare provider office or Emergency Department visit or hospitalization) or receives a new prescription for systemic corticosteroids.


Secondary Outcome Measures :
  1. Comparison of the proportion of participants experiencing an asthma exacerbation during the 14 days after LAIV4 vs. IIV4 [ Time Frame: Day 15 ]
    For this study, asthma exacerbation will be defined as: any acute episode of progressively worsening shortness of breath (dyspnea), cough, wheezing, chest tightness, and/or respiratory distress during the 14 days (until day 15) after influenza vaccination for which the patient seeks unscheduled medical attention (e.g., healthcare provider office or Emergency Department visit or hospitalization) or receives a new prescription for systemic corticosteroids.

  2. Comparison of the proportion of participants with asthma symptoms and unscheduled albuterol use during the 14 days after receipt of LAIV4 or IIV4 (each is assessed separately). [ Time Frame: Day 15 ]
    Cough, wheezing, tightness in chest, nighttime awakening and unscheduled albuterol use will all be assessed by parent self-report

  3. Comparison of the proportion of participants who experience a clinically significant decrease in peak flow measurement from baseline during the 14 days after LAIV4 or IIV4 [ Time Frame: Baseline, Day 15 ]
    For purposes of this measure, a clinically significant decrease in peak flow is defined as: a decrease of ≥20% in PEFR from baseline PEFR



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Children between 5-11 years of age, inclusive, at enrollment
  • Participant must have a current diagnosis of persistent asthma (Physician diagnosis of asthma and current prescribed use of a long-acting controller medication. For purposes of this study, we have considered "controller" medications to be any single or combination use of long-acting medications used to prevent asthma exacerbations and to achieve long-term control of asthma (as compared to short-acting rescue medication).)
  • Parent(s) or legal guardian(s) must provide written, informed consent and participant must provide assent as appropriate for age prior to initiation of study procedures and according to local IRB requirements
  • Parent(s) or legal guardian(s) and participant must be willing and able to comply with planned study procedures and be available for all study visits
  • Is in good health, other than their asthma, as determined by medical history
  • English or Spanish literate (only English-speaking participants will be included at the Cincinnati and Duke sites)
  • Intention of being available for entire study period and complete all relevant study procedures, including follow-up using at least one of the following methods: phone calls, text messages, or emails

Exclusion Criteria:

  • Acute illness and/or a reported oral temperature of ≥ 100.4°F within 72 hours prior to enrollment (this may result in a temporary delay of vaccination)
  • Use of antipyretic medication during the preceding 24 hours that might mask a fever (this may result in a temporary delay of vaccination)
  • History of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of any influenza vaccine or after any component of the influenza vaccine, including egg protein.
  • Receipt of any licensed vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to vaccination or planned receipt of any licensed vaccine within 42 days after vaccination
  • Receipt of current year's (2018-2019 influenza season) licensed influenza vaccine for children 9-11 years (only). (Clarification: Children aged 5-8 years are permitted to be enrolled if they have received zero or one dose of the 2018-2019 influenza season vaccine, and require two doses of the 2018-2019 influenza vaccine.)
  • Received an investigational agent (licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication) in the 28 days prior to enrollment or planned receipt before 42 days after vaccination
  • Have immunosuppression as a result of an underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months
  • Have taken ≥20mg/day of prednisone or its equivalent, for 14 days or more within the past 28 days
  • Have known active neoplasm or a history of any hematologic malignancy
  • Has had a previous exacerbation of their asthma symptoms requiring systemic steroids within the prior 28 days, or has had a life-threatening exacerbation of asthma in the past two years (e.g. hypoxic seizure, mechanical ventilation)
  • Received influenza antiviral medication within 48 hours prior to study vaccination
  • History of Guillian-Barré syndrome within 6 weeks of previous influenza vaccination
  • Have any condition that, in the opinion of the investigator, would interfere with the evaluation of the responses or would place the participant at unacceptable risk of injury
  • Has a positive urine or serum pregnancy test within 24 hours prior to vaccination in a post-menarchal female. LAIV is not recommended for use in pregnant females.
  • Currently taking aspirin or aspirin-containing products
  • Any parent(s) or legal guardian(s) who is an immediate relative of study staff or is an employee supervised by study staff.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03600428


Locations
Layout table for location information
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University Medical Center
Centers for Disease Control and Prevention
Duke University
Children's Hospital Medical Center, Cincinnati
Investigators
Layout table for investigator information
Principal Investigator: Buddy Creech, MD, MPH Vanderbilt University Medical Center
Layout table for additonal information
Responsible Party: Buddy Creech, Associate Professor of Pediatrics, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier: NCT03600428    
Other Study ID Numbers: 181211
200-2012-50430 Task Order 0005 ( Other Grant/Funding Number: Centers for Disease Control and Prevention )
First Posted: July 26, 2018    Key Record Dates
Last Update Posted: April 10, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Buddy Creech, Vanderbilt University Medical Center:
asthma
influenza vaccine
inactivated influenza vaccine
live attenuated influenza vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Asthma
Respiratory Sounds
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Signs and Symptoms, Respiratory
Signs and Symptoms
Vaccines
Immunologic Factors
Physiological Effects of Drugs